Hongyu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongyu Wang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Jianming Ying
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
41 shared publications - Junling Li
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
41 shared publications - Xin Zhang
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
41 shared publications - Xuezhi Hao
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
41 shared publications - Boyang Sun
State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences Beijing China
32 shared publications - Hua Bai
CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
32 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table TS1 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
Clinicopathologic characteristics of patients in cohort 3.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS1 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
Clinicopathologic characteristics of patients in cohort 3.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
One MET-FISH-negative patient was classified as having MET polysomy by NGS
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
One MET-FISH-negative patient was classified as having MET polysomy by NGS
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
One MET-FISH-positive tumor was identified as negative by NGS
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
One MET-FISH-positive tumor was identified as negative by NGS
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table TS2 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
Summary of MET status tested by NGS, MET inhibitors with clinical outcome and dynamic changes in gene alterations in cohort 3
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS2 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
Summary of MET status tested by NGS, MET inhibitors with clinical outcome and dynamic changes in gene alterations in cohort 3
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table TS1 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
Clinicopathologic characteristics of patients in cohort 3.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS1 from Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors
Clinicopathologic characteristics of patients in cohort 3.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
One MET-FISH polysomy tumor was classified as negative using the NGS assay.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
One MET-FISH polysomy tumor was classified as negative using the NGS assay.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Table TS2 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
Summary of MET status tested by NGS, MET inhibitors with clinical outcome and dynamic changes in gene alterations in cohort 3
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable TS2 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
Summary of MET status tested by NGS, MET inhibitors with clinical outcome and dynamic changes in gene alterations in cohort 3
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
One MET-FISH-negative patient was classified as having MET polysomy by NGS
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
One MET-FISH-negative patient was classified as having MET polysomy by NGS